Blood Glucose Fluctuations in Type 2 Diabetes Patients Treated with Multiple Daily Injections

To compare blood glucose fluctuations in type 2 diabetes mellitus (T2DM) patients were treated using three procedures: insulin intensive therapy which is continuous subcutaneous insulin infusion (CSII), MDI3 (three injections daily), and MDI4 (four injections daily). T2DM patients were hospitalized...

Full description

Bibliographic Details
Main Authors:	Li, Feng-fei, Fu, Li-yuan, Zhang, Wen-li, Su, Xiao-fei, Wu, Jin-dan, Sun, Jin, Ye, Lei, Ma, Jian-hua
Format:	Online
Language:	English
Published:	Hindawi Publishing Corporation 2016
Online Access:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4709669/

id	pubmed-4709669
recordtype	oai_dc
spelling	pubmed-47096692016-02-02 Blood Glucose Fluctuations in Type 2 Diabetes Patients Treated with Multiple Daily Injections Li, Feng-fei Fu, Li-yuan Zhang, Wen-li Su, Xiao-fei Wu, Jin-dan Sun, Jin Ye, Lei Ma, Jian-hua Research Article To compare blood glucose fluctuations in type 2 diabetes mellitus (T2DM) patients were treated using three procedures: insulin intensive therapy which is continuous subcutaneous insulin infusion (CSII), MDI3 (three injections daily), and MDI4 (four injections daily). T2DM patients were hospitalized and were randomly assigned to CSII, aspart 30-based MDI3, and glargine based MDI4. Treatments were maintained for 2-3 weeks after the glycaemic target was reached. After completing the baseline assessment, 6-day continuous glucose monitoring (CGM) was performed before and after completion of insulin treatment. Treatment with CSII provided a greater improvement of blood glucose fluctuations than MDI (MDI3 or MDI4) therapy either in newly diagnosed or in long-standing T2DM patients. In long-standing diabetes patients, the MDI4 treatment group had significantly greater improvement of mean amplitude glycemic excursion (MAGE) than the MDI3 treatment group. However, in patients with newly diagnosed diabetes, there were no significant differences in the improvement of MAGE between MDI3 and MDI4 groups. Glargine based MDI4 therapy provided better glucose fluctuations than aspart 30-based MDI3 therapy, especially in long-standing T2DM patients, if CSII therapy was not available. Hindawi Publishing Corporation 2016 2015-12-29 /pmc/articles/PMC4709669/ /pubmed/26839889 http://dx.doi.org/10.1155/2016/1028945 Text en Copyright © 2016 Feng-fei Li et al. https://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
repository_type	Open Access Journal
institution_category	Foreign Institution
institution	US National Center for Biotechnology Information
building	NCBI PubMed
collection	Online Access
language	English
format	Online
author	Li, Feng-fei Fu, Li-yuan Zhang, Wen-li Su, Xiao-fei Wu, Jin-dan Sun, Jin Ye, Lei Ma, Jian-hua
spellingShingle	Li, Feng-fei Fu, Li-yuan Zhang, Wen-li Su, Xiao-fei Wu, Jin-dan Sun, Jin Ye, Lei Ma, Jian-hua Blood Glucose Fluctuations in Type 2 Diabetes Patients Treated with Multiple Daily Injections
author_facet	Li, Feng-fei Fu, Li-yuan Zhang, Wen-li Su, Xiao-fei Wu, Jin-dan Sun, Jin Ye, Lei Ma, Jian-hua
author_sort	Li, Feng-fei
title	Blood Glucose Fluctuations in Type 2 Diabetes Patients Treated with Multiple Daily Injections
title_short	Blood Glucose Fluctuations in Type 2 Diabetes Patients Treated with Multiple Daily Injections
title_full	Blood Glucose Fluctuations in Type 2 Diabetes Patients Treated with Multiple Daily Injections
title_fullStr	Blood Glucose Fluctuations in Type 2 Diabetes Patients Treated with Multiple Daily Injections
title_full_unstemmed	Blood Glucose Fluctuations in Type 2 Diabetes Patients Treated with Multiple Daily Injections
title_sort	blood glucose fluctuations in type 2 diabetes patients treated with multiple daily injections
description	To compare blood glucose fluctuations in type 2 diabetes mellitus (T2DM) patients were treated using three procedures: insulin intensive therapy which is continuous subcutaneous insulin infusion (CSII), MDI3 (three injections daily), and MDI4 (four injections daily). T2DM patients were hospitalized and were randomly assigned to CSII, aspart 30-based MDI3, and glargine based MDI4. Treatments were maintained for 2-3 weeks after the glycaemic target was reached. After completing the baseline assessment, 6-day continuous glucose monitoring (CGM) was performed before and after completion of insulin treatment. Treatment with CSII provided a greater improvement of blood glucose fluctuations than MDI (MDI3 or MDI4) therapy either in newly diagnosed or in long-standing T2DM patients. In long-standing diabetes patients, the MDI4 treatment group had significantly greater improvement of mean amplitude glycemic excursion (MAGE) than the MDI3 treatment group. However, in patients with newly diagnosed diabetes, there were no significant differences in the improvement of MAGE between MDI3 and MDI4 groups. Glargine based MDI4 therapy provided better glucose fluctuations than aspart 30-based MDI3 therapy, especially in long-standing T2DM patients, if CSII therapy was not available.
publisher	Hindawi Publishing Corporation
publishDate	2016
url	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4709669/
_version_	1613522972439478272

Blood Glucose Fluctuations in Type 2 Diabetes Patients Treated with Multiple Daily Injections

Similar Items